Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is one of the most promising healthcare stocks according to Wall Street analysts. On June 10, GENESIS Pharma announced the expansion of its commercial partnership with Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) to cover four Nordic countries, that is, Sweden, Finland, Denmark, and Norway. GENESIS is an Athens-based biopharma company and the expanded collaboration gives it rights to commercialize Alnylam’s RNAi therapeutics for serious heart muscle diseases and rare genetic conditions across the new territory.
The two companies started to work together in 2019, and at that time, the collaboration only covered Southeast Europe. Without the four additional countries, the collaboration covers 13 markets.
RNAi, or RNA interference, is Alnylam’s proprietary technology that silences the genes responsible for producing disease-causing proteins. In short, it works by cutting off diseases at a molecular level before they fully take hold. This technology is a key part of the company’s portfolio.
The expanded relationship means that Alnylam now has four new markets for the technology. According to Norton Oliveira, Senior Vice-President and Head of Partner and Emerging Markets at Alnylam, the expansion also means that the company “can continue to address the needs of even more patients and their families.”
For Constantinos Evripides, Managing Director of GENESIS, the expanded relationship is an important push the company needed to strengthen their European footprint. “By combining Alnylam’s pioneering science with our strong regional expertise in bringing innovation closer to patients, we continue to expand our reach and enhance the value we deliver across healthcare systems,” Evripides said.
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) is a commercial-stage biopharmaceutical company pioneering RNA interference therapeutics. It discovers, develops, and commercializes medicines that silence disease-causing genes, and it has six approved medicines.
While we acknowledge the potential of ALNY as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: 12 High-Growth Micro-Cap Stocks to Buy Now and 10 Best Long-Term Stocks to Invest In According to Bill & Melinda Gates Foundation Trust.
Disclosure: None. Follow Insider Monkey on Google News.